标题
State-of-the-art strategies for targeting the DNA damage response in cancer
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 16, Issue 2, Pages 81-104
出版商
Springer Nature
发表日期
2018-10-24
DOI
10.1038/s41571-018-0114-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germlineBRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)
- (2018) SM Domchek et al. CANCER RESEARCH
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- (2018) Yi-Mi Wu et al. CELL
- Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
- (2018) David S. Hong et al. CLINICAL CANCER RESEARCH
- The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities
- (2018) Kathleen N. Moore et al. GYNECOLOGIC ONCOLOGY
- A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.
- (2018) Fatima Karzai et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Noel Clarke et al. LANCET ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Target engagement imaging of PARP inhibitors in small-cell lung cancer
- (2018) Brandon Carney et al. Nature Communications
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
- (2018) Stephen J. Pettitt et al. Nature Communications
- Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers
- (2018) Daniel J. McGrail et al. Nature Communications
- Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
- (2018) Theo A. Knijnenburg et al. Cell Reports
- Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
- (2018) J Ettl et al. ANNALS OF ONCOLOGY
- Replication Protein A Availability During DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells
- (2018) François Bélanger et al. CANCER RESEARCH
- Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+).
- (2018) Jennifer Keating Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
- (2017) Stephanie A. Yazinski et al. GENES & DEVELOPMENT
- A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers
- (2017) Kim A. Reiss et al. GYNECOLOGIC ONCOLOGY
- PARP inhibitors: Clinical utility and possibilities of overcoming resistance
- (2017) Benjamin G. Bitler et al. GYNECOLOGIC ONCOLOGY
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
- (2017) Amit M. Oza et al. GYNECOLOGIC ONCOLOGY
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
- (2017) Diana Mandelker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma
- (2017) Koji Shindo et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair
- (2017) Rossella Parrotta et al. Journal of Thoracic Oncology
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Missing a GOLDen opportunity in gastric cancer
- (2017) Elizabeth Smyth LANCET ONCOLOGY
- Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?
- (2017) Antonio González Martín LANCET ONCOLOGY
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Yung-Jue Bang et al. LANCET ONCOLOGY
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer
- (2017) Thomas Wehler et al. LUNG CANCER
- A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
- (2017) Paz Polak et al. NATURE GENETICS
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Functional variomics and network perturbation: connecting genotype to phenotype in cancer
- (2017) Song Yi et al. NATURE REVIEWS GENETICS
- Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
- (2017) Kenneth M. Felsenstein et al. Nature Reviews Urology
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAD51 interconnects between DNA replication, DNA repair and immunity
- (2017) Souparno Bhattacharya et al. NUCLEIC ACIDS RESEARCH
- EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
- (2017) H Yamaguchi et al. ONCOGENE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
- (2017) Mohammad Asim et al. Nature Communications
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions
- (2017) Susan M. Domchek Cancer Discovery
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
- (2017) David Quigley et al. Cancer Discovery
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model
- (2017) Gerben R. Borst et al. Oncotarget
- Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling
- (2017) Styliani Karanika et al. Cell Reports
- BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
- (2017) Sergey Karakashev et al. Cell Reports
- Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
- (2017) A. L. Ho et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol
- (2016) F. Meric-Bernstam et al. ANNALS OF ONCOLOGY
- A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation
- (2016) J.K. Litton et al. ANNALS OF ONCOLOGY
- PARP inhibitors: the race is on
- (2016) Jessica S Brown et al. BRITISH JOURNAL OF CANCER
- Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer
- (2016) Nidal E. Muvarak et al. CANCER CELL
- Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations
- (2016) Vasiliki Michalarea et al. CANCER RESEARCH
- Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792):
- (2016) Geoffrey Shapiro et al. CANCER RESEARCH
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
- (2016) Hyoung Kim et al. CLINICAL CANCER RESEARCH
- PARP inhibitor combination therapy
- (2016) Amy Dréan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers
- (2016) T.A. Yap et al. EUROPEAN JOURNAL OF CANCER
- Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells
- (2016) Hee-Jun Kim et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
- (2016) David Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study
- (2016) Pierre Chabot et al. JOURNAL OF NEURO-ONCOLOGY
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
- (2016) Mary B. Daly et al. Journal of the National Comprehensive Cancer Network
- Monogenic and polygenic determinants of sarcoma risk: an international genetic study
- (2016) Mandy L Ballinger et al. LANCET ONCOLOGY
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
- (2016) Jonathan A Ledermann et al. LANCET ONCOLOGY
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
- (2016) Yi Du et al. NATURE MEDICINE
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- (2016) Jessica S. Brown et al. Cancer Discovery
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
- (2016) Petra ter Brugge et al. JNCI-Journal of the National Cancer Institute
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
- (2016) Kasmintan A. Schrader et al. JAMA Oncology
- Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
- (2015) J. Bendell et al. ANNALS OF ONCOLOGY
- Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
- (2015) Sophia X. Pfister et al. CANCER CELL
- Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort
- (2015) Ursula A. Matulonis et al. CANCER RESEARCH
- mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer
- (2015) W. Mo et al. CLINICAL CANCER RESEARCH
- Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
- (2015) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor STING to Promote Anti-Microbial Innate Immunity
- (2015) Anetta Härtlova et al. IMMUNITY
- Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
- (2015) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115
- (2015) Deborah S. Mortensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity
- (2015) Timothy A. Yap et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
- (2015) Raphael Ceccaldi et al. NATURE
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- ATM and ATR as therapeutic targets in cancer
- (2015) Anika Maria Weber et al. PHARMACOLOGY & THERAPEUTICS
- Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer
- (2015) Linda Henneman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
- (2015) R. L. Flynn et al. SCIENCE
- Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition
- (2015) Lynnette R. Ferguson et al. SEMINARS IN CANCER BIOLOGY
- ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
- (2015) J. Shen et al. Cancer Discovery
- Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma
- (2015) F. Cottini et al. Cancer Discovery
- Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition
- (2015) Fiona K. Middleton et al. Oncotarget
- A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments
- (2015) Kareem N. Mohni et al. PLoS One
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
- (2014) Edward Sausville et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
- (2014) Eiji Kubota et al. CELL CYCLE
- Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
- (2014) D. Karnak et al. CLINICAL CANCER RESEARCH
- A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001
- (2014) Deborah T. Blumenthal et al. International Journal of Clinical Oncology
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
- (2014) O. S. Chao et al. MOLECULAR CANCER RESEARCH
- An update on PARP inhibitors—moving to the adjuvant setting
- (2014) Amir Sonnenblick et al. Nature Reviews Clinical Oncology
- A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation
- (2014) Y Yan et al. ONCOGENE
- Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy
- (2014) H. Al-Ahmadie et al. Cancer Discovery
- SETD2-Dependent Histone H3K36 Trimethylation Is Required for Homologous Recombination Repair and Genome Stability
- (2014) Sophia X. Pfister et al. Cell Reports
- Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
- (2013) Takashi Seto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- (2013) A. M. Aparicio et al. CLINICAL CANCER RESEARCH
- Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
- (2013) R. J. Cardnell et al. CLINICAL CANCER RESEARCH
- PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks
- (2013) Michael J. Metzger et al. DNA REPAIR
- A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
- (2013) Joyce F. Liu et al. EUROPEAN JOURNAL OF CANCER
- Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies
- (2013) Thomas P Matthews et al. Expert Opinion on Drug Discovery
- ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
- (2013) Maria Gilardini Montani et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
- (2013) A. D. Guertin et al. MOLECULAR CANCER THERAPEUTICS
- Discrepancies in drug sensitivity
- (2013) John N. Weinstein et al. NATURE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Concordance of ATM (Ataxia Telangiectasia Mutated) Immunohistochemistry between Biopsy or Metastatic Tumor Samples and Primary Tumors in Gastric Cancer Patients
- (2013) Hee Sung Kim et al. PATHOBIOLOGY
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
- (2013) H. Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of Resistance to PARP Inhibitors—Three and Counting
- (2013) Tito Fojo et al. Cancer Discovery
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
- (2012) Cynthia X. Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
- (2012) E Dean et al. BRITISH JOURNAL OF CANCER
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
- (2012) Z. C. Wang et al. CLINICAL CANCER RESEARCH
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
- (2012) A. Rajan et al. CLINICAL CANCER RESEARCH
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
- (2012) A. G. Patel et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
- (2012) J. E. Karp et al. CLINICAL CANCER RESEARCH
- Increased PARP-1 Association with DNA in Alkylation Damaged, PARP-Inhibited Mouse Fibroblasts
- (2012) P. S. Kedar et al. MOLECULAR CANCER RESEARCH
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
- (2011) K. A. Bridges et al. CLINICAL CANCER RESEARCH
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Alternative lengthening of telomeres: models, mechanisms and implications
- (2010) Anthony J. Cesare et al. NATURE REVIEWS GENETICS
- Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?
- (2009) M. Ali et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
- (2009) Jennifer A. Quinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- (2009) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started